March 2015 - Asepticenclosures

Recall of Ultra ZX Since It Contains Undeclared Sibutramine and Phenolphthalein

FOR IMMEDIATE RELEASE — March 10, 2015 — Miami, Florida — UltraZx, Labs, L.L.C. is voluntarily recalling “UltraZx” weight loss supplements. This product has been found to contain undeclared Sibutramine and phenolphthalein. FDA laboratory analysis of confirmed that UltraZx contains sibutramine and phenolphthalein. Sibutramine is a controlled substance that was removed from the market in October …

Recall of Ultra ZX Since It Contains Undeclared Sibutramine and Phenolphthalein Read More »

FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another Direct Acting Antiviral drug

Leave a Comment / blog, FDA News, Hospital Industry News, Pharmaceutical Industry News, Research News / By admin

On March 24, 2015, FDA is warning that serious slowing of the heart rate can occur when the antiarrhythmic drug amiodarone is taken together with either the hepatitis C drug Harvoni (active ingredients ledipasvir and sofosbuvir) or with Sovaldi (active ingredient sofosbuvir) taken in combination with another direct acting antiviral for the treatment of hepatitis …

FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir Harvoni or Sovaldi in combination with another Direct Acting Antiviral drug Read More »

FDA Launches Drug Shortages Mobile App

Leave a Comment / blog, Compounding News, FDA News, Hospital Industry News, Pharmaceutical Industry News / By admin

The U.S. Food and Drug Administration launched the agency’s first mobile application (app) specifically designed to speed public access to valuable information about drug shortages. The app identifies current drug shortages, resolved shortages and discontinuations of drug products. Drugs in short supply can delay or deny needed care for patients. Drug shortages may also lead health …

FDA Launches Drug Shortages Mobile App Read More »

Non-FDA Approved Hormone Therapies on the Rise

Leave a Comment / blog, Compounding News, FDA News, Hospital Industry News, Pharmaceutical Industry News, Research News / By admin

Use of potentially risky, non-FDA approved hormone therapies may soon be as common as use of FDA-approved hormone therapies, according to a study by University of Virginia gynecology researcher JoAnn Pinkerton. Between 28 and 68 percent of menopausal hormone users take “compounded therapies,” hormone formulations that have been compounded by pharmacists, but whose precise ingredients have not …

Non-FDA Approved Hormone Therapies on the Rise Read More »

FDA proposal would allow drugmakers to rebut warnings

2 Comments / blog, Compounding News, FDA News, Pharmaceutical Industry News / By admin

The Food and Drug Administration is proposing to allow pharmaceutical companies to contradict official safety warnings in sales presentations to customers. While an FDA warning about a drug’s dangers can scare off buyers, the new proposal would allow the companies to present customers with information that undermines official warnings as long as it comes from …

FDA proposal would allow drugmakers to rebut warnings Read More »

Heritage Pharmaceuticals Initiates a Nationwide Voluntary Recall of Colistimethate for Injection USP, 150 mg and Rifampin for Injection USP, 600 mg/vial Due to a Lack of Sterility Assurance

Leave a Comment / blog, Company News, Compounding News, FDA News, Hospital Industry News, Pharmaceutical Industry News, Research News / By admin

Eatontown, NJ, Heritage Pharmaceuticals Inc. (Heritage) today announced the voluntary nationwide recall of ten (10) lots of Colistimethate for Injection, USP, 150 mg Single-Dose vial (NDC 23155-193-31) and three (3) lots of Rifampin for Injection, USP, 600 mg Single-Dose vial (NDC 23155-340-31) manufactured by Emcure Pharmaceuticals Ltd. and distributed by Heritage. Both products are sold …

Heritage Pharmaceuticals Initiates a Nationwide Voluntary Recall of Colistimethate for Injection USP, 150 mg and Rifampin for Injection USP, 600 mg/vial Due to a Lack of Sterility Assurance Read More »

FDA issues new draft documents related to compounding of human drugs

Leave a Comment / blog, Compounding News, FDA News, Pharmaceutical Industry News, Research News / By admin

Documents include draft guidances on outsourcing facility registration; outsourcing facility adverse event reporting; drug repackaging; mixing, diluting, and repackaging biological products; and a draft Memorandum of Understanding with the states. Today, the U.S. Food and Drug Administration issued five draft documents related to drug compounding and repackaging that will help entities comply with important public …

FDA issues new draft documents related to compounding of human drugs Read More »

Our XLTC Isolators

Leave a Comment / blog, Company News, Compounding News, featured / By admin

One of the most recent additions to our product line are our XLTC Isolators that incorporate a completely segmented, large and aseptic area for incoming product to be properly disinfected.

Month: March 2015